Castillo-Henríquez, L.; Sanabria-Espinoza, P.; Murillo-Castillo, B.; Montes de Oca-Vásquez, G.; Batista-Menezes, D.; Calvo-Guzmán, B.; Ramírez-Arguedas, N.; Vega-Baudrit, J. Topical Chitosan-Based Thermo-Responsive Scaffold Provides Dexketoprofen Trometamol Controlled Release for 24 h Use. Pharmaceutics2021, 13, 2100.
Castillo-Henríquez, L.; Sanabria-Espinoza, P.; Murillo-Castillo, B.; Montes de Oca-Vásquez, G.; Batista-Menezes, D.; Calvo-Guzmán, B.; Ramírez-Arguedas, N.; Vega-Baudrit, J. Topical Chitosan-Based Thermo-Responsive Scaffold Provides Dexketoprofen Trometamol Controlled Release for 24 h Use. Pharmaceutics 2021, 13, 2100.
Castillo-Henríquez, L.; Sanabria-Espinoza, P.; Murillo-Castillo, B.; Montes de Oca-Vásquez, G.; Batista-Menezes, D.; Calvo-Guzmán, B.; Ramírez-Arguedas, N.; Vega-Baudrit, J. Topical Chitosan-Based Thermo-Responsive Scaffold Provides Dexketoprofen Trometamol Controlled Release for 24 h Use. Pharmaceutics2021, 13, 2100.
Castillo-Henríquez, L.; Sanabria-Espinoza, P.; Murillo-Castillo, B.; Montes de Oca-Vásquez, G.; Batista-Menezes, D.; Calvo-Guzmán, B.; Ramírez-Arguedas, N.; Vega-Baudrit, J. Topical Chitosan-Based Thermo-Responsive Scaffold Provides Dexketoprofen Trometamol Controlled Release for 24 h Use. Pharmaceutics 2021, 13, 2100.
Abstract
Chronic and non-healing wounds demand personalized and more effective therapies for treating complications and improve patient adherence. This work aims to develop a suitable chitosan-based scaffold to provide 24 hours controlled release of DKT, by taking advantage of chitosan’s thermo-responsive behavior as well as local hyperthermia in wounds. Three formulation prototypes were developed using chitosan (F1), 2:1 chitosan: PVA (F2), and 1:1 chitosan:gelatin (F3). Compatibility tests were done by DSC, TG, and IR spectroscopy. SEM was employed to examine the morphology of the surface and inner layers from the scaffolds. In vitro release studies were performed at 32 °C and 38 °C to evaluate the release profiles, which were later adjusted to different kinetic models for the best formulation. F3 showed the most controlled release of DKT at 32 °C for 24 hours (77.75 ± 2.72 %), and reduced the burst release in the initial 6 hours (40.18 ± 1.00 %), while at 38 °C the release reached 88.52 ± 2.07 % at 12 hours. The release profile for this formulation fits with Hixson-Crowell and Korsmeyer-Peppas kinetic models at both temperatures. Therefore, the developed chitosan/gelatin thermo-responsive scaffold provides a suitable system for wound healing with a controlled release of DKT for 24 hour-use, which can overcome adherence issues and wound complications.
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.